scRNA-Seq analysis of a glioblastoma patient sample after Vortioxetine or DMSO treatment

Vortioxetine is the neuroactive drug with the highest ex vivo anti-glioblastoma efficacy across patients measured in our study. We used single-cell RNA sequencing (scRNA-seq) to analyze the transcriptomic response to Vortioxetine treatment. Overall design: Dissociated and cryopreserved single-cell suspensions of a patient sample P024 were processed by fluorescence-activated cell sorting (FACS) to isolate viable CD45+ immune cells and CD45- glioblastoma cells. Sorted cells were subsequently treated with Vortioxetine or DMSO for 3 hours before proceeding to generate scRNA-Seq libraries.